Use of botulinum toxin type A in reconstructive surgery in patients with breast cancer (literature review)

According to the analyzed literature, the use of botulinum toxin type A is promising as an auxiliary method for simultaneous or delayed breast reconstruction using a subpectoral silicone implant or tissue expander. This method is safe and simple. Relaxation of the large pectoral muscle both intraoperatively and in the postoperative period reduces the intensity of pain, accelerates the rehabilitation of patients. Botulinum toxin therapy prevents the animation and deformation of the reconstructed breast. The effect after injection of botulinum toxin persists for 6-8 months and for a long time there is no need for analgesic therapy. According to the literature, this technique for reconstructive plastic surgery in patients with breast cancer significantly improves the quality of life of patients by reducing pain, preventing deformation and contraction of the large pectoral muscle. Conclusion. The literature analysis evaluates the effectiveness of botulinum toxin preparations for pain after reconstructive plastic surgery on the breast using a subpectoral space. The possibilities of therapeutic use of botulinum toxin preparations as an analgesic are known, but are little used in practice. This direction is promising. Given the small number of literary publications on this subject, it is necessary to conduct further research in this direction.

1. Kaprin A. D., Starinskij V. V., Petrova G. V. Malignant neoplasms in Russia in 2018. Moscow, P. A. Herzen medical Institute-branch of the Federal state budgetary institution «NMIC of radiology» of the Ministry of health of Russia. 2019; 250.

2. Kaprin A. D., Starinskij V. V., Petrova G. V. State of cancer care in Russia in 2018. Moscow, P. A. Herzen medical Institute-branch of the Federal state budgetary institution «NMIC of radiology» of the Ministry of health of Russia. 2019; 236.

3. Figus A., Mazzocchi M., Dessy L. A., Curinga G., Scuderi N. Treatment of muscular contraction deformities with botulinum toxin type A after latissimus dorsi flap and sub-pectoral implant breast reconstruction. Journal of Plastic, Reconstructive & Aesthetic Surgery. 2009; 62 (7): 869-875. https://doi.org/10.1016/j.bjps.2007.07.025.

4. Layeeque R., Hochberg J., Siegel E., Kunkel K., Kepple J., Henry-Tillman R. S, Dunlap M., Seibert J., Klimberg V. S. Botulinum toxin infiltration for pain control after mastectomy and expander reconstruction. Annals of Surgery. 2004; 240 (4): 608. https://doi.org/10.1097/01.sla.0000141156.56314.1f.

5. Winocour S., Murad M. H., Bidgoli-Moghaddam M., Jacobson S. R., Bite U., Saint-Cyr M., Tran N. V., Lemaine V. A systematic review of the use of Botulinum toxin type A with subpectoral breast implants. Journal of Plastic, Reconstructive & Aesthetic Surgery. 2014; 67 (1): 34-41. https://doi.org/10.1016/j.bjps.2013.09.012.

6. Lamanna C., Spero L., Schantz E. J. Dependence of time to death on molecular size of botulinum toxin. Infection and Immunity. 1970; 1 (4): 423. https://doi.org/10.1128/IAI.1.4.423-424.1970.

7. Schantz E. J. Some chemical and physical properties of Clostridium botulinum toxins in culture. Japanese journal of microbiology. 1967; 11 (4): 380-383. https://doi.org/10.1111/j.1348-0421.1967.tb00361.x.

8. Scott A. B., Rosenbaum A., Collins C. C. Pharmacologic weakening of extraocular muscles. Investigative Ophthalmology & Visual Science. 1973; 12 (12): 924-927. PMID: 4203467.

9. Scott A. B. Botulinum toxin injection of eye muscles to correct strabismus. Transactions of the American Ophthalmological Society. 1981; 79:734-770. PMID: 7043872.

10. Scott A. B., Magoon E. H., McNeer K.W., Stager D. R. Botulinum treatment of childhood strabismus. Ophthalmology. 1990; 97 (11): 1434-1438. https://doi.org/10.1016/s0161-6420(90)32390-4.

11. Brin M. F., Blitzer A. Botulinum Toxin: Dangerous Terminology Errors. Journal of the Royal Society of Medicine. 1993; 86 (8): 493.

12. Barbehenn E., Lurie P., Stark Sh., S. Wolfe. United States Department of Health and Human Services. Public Citizen Health Research Group. 2009; 1-18.

13. U. S. Food and Drug Administration (FDA). Archived from the original on 6 July 2010. 2010; 2-15.

14. Margolina A. A., Hernandez E. I. New cosmetology. M: LLC «Firm CLAVEL». 2007; 2: 418.

15. Meng J., Wang J., Lawrence G., Dolly J. O. Synapto-brevin I mediates exocytosis of CGRP from sensory neurons and inhibition by botulinum toxins reflects their anti-nociceptive potential. Journal of cell science. 2007; 120 (16): 2864-2874. https://doi.org/10.1242/jcs.012211.

16. Cui M., Li Z., You S., Khanijou S., Aoki K. Mechanisms of the antinociceptive effect of subcutaneous Botox: inhibition of peripheral and central nociceptive processing. Naunyn-Schmiedebergs Archives of Pharmacology. 2002; 365: 17.

17. Mittal S. O. M., Jabbari B. Botulinum Neurotoxins and Cancer-A Review of the Literature. Toxins. 2020; 12 (1): 32. https://doi.org/10.3390/toxins12010032.

18. Jeong H. S., Lee B. H., Sung H. M., Park S. Y., Ahn D. K., Jung M. S., Suh I. S. Effect of Botulinum Toxin Type A on Differentiation of Fibroblasts Derived from Scar Tissue. Plastic and Reconstructive Surgery. 2015; 136 (2): 171e-178e. https://doi.org/10.1097/PRS.0000000000001438.

19. Fishman L. M., Anderson C., Rosner B. BOTOX and physical therapy in the treatment of piriformis syndrome. American journal of physical medicine & rehabilitation. 2002; 81 (12): 936-942. https://doi.org/10.1097/00002060-200212000-00009.

20. Foster L., Clapp L., Erickson M., Jabbari B. Botulinum toxin A and chronic low back pain. A randomized, double-blind study. Neurology. 2001; 56 (10): 1290-1293. https://doi.org/10.1212/wnl.56.10.1290.

21. Porta M. A comparative trial of botulinum toxin type A and methylprednisolone for the treatment of myofascial pain syndrome and pain from chronic muscle spasm. Pain. 2000; 85- (1-2): 101-105. https://doi.org/10.1016/s0304-3959(99)00264-x.

22. Altieri A., Brongo S., Mele C. M., Amoroso A., D'Andrea F. The botulinum toxin in breast reconstruction. RivistaItaliana di Chirurgia Plastica. 2006; 38: 127e.

23. Hao L., Clarke C. P. Persistent twitchihg of the latissimus dorsimuscle after a posterolateral thoracotomy. ANZ journal of surgery. 2002; 72 (9): 680-681. https://doi.org/10.1046/j.1445-2197.2002.02501.x

24. Munhoz A. M., Montag E., Fels K. W., Arruda E. G.P., Sturtz G. P., Aldrighi C., Gemperli R., Ferreira M. C. Outcome analysis of breast-conservation surgery and immediate latissimus dorsi flap reconstruction in patients with T1 to T2 breast cancer. Plastic and reconstructive surgery. 2005; 116 (3): 741-752. https://doi.org/10.1097/01.prs.0000176251.15140.36.

25. O'Donnell C. J. Pectoral muscle spasms after mastectomy successfully treated with botulinum toxin injections. PM&R. 2011; 8 (3): 781-782. https://doi.org/10.1016/j.pmrj.2011.02.023.

26. Gabriel A., Champaneria M. C., Maxwell G. P. The efficacy of botulinum toxin A in post-mastectomy breast reconstruction: a pilot study. Aesthetic Surgery Journal. 2015; 35 (4): 402-409. https://doi.org/10.1093/asj/sjv040

27. Irkoren S., Ozkan H. S., Ceylan E., Sivrioglu N., Tataroglu C., Durum Y. The Effect of Botox on the Implant Stabilization and Capsular Formation: An Experimental Study. Annals of Plastic Surgery. 2015; 75 (1): 91-97. https://doi.org/10.1097/SAP.0000000000000005.

28. Ivanov V. G., Volokh M. A., Ermilova E. V., Fedosov S. I., Voznyuk I. A., Vorob'eva M. N. Sobstvennyi opyt ispol'zovaniya botulotoksina tipa A (Botox) v rekonstruktivnoi khirurgii molochnoi zhelezy. Povolzhskii onkologicheskii vestnik. 2016; 1 (23): 55-59.

29. De Groef A., Devoogdt N., Van Kampen M., Nevelsteen I., Smeets A., Neven P., Geraerts I.., Dams L, Van der Gucht E., Debeer P. Effectiveness of Botulinum Toxin A for Persistent Upper Limb Pain After Breast Cancer Treatment: A Double-Blinded Randomized Controlled Trial. Archives of physical medicine and rehabilitation. 2018; 99 (7): 13421351. https://doi.org/10.1016/j.apmr.2017.12.032